长期替比夫定治疗后血清激肽释放酶-8水平升高。
Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment.
作者信息
Wang Haw-En, Lin Chih-Lang, Pan Tai-Long, Yeh Chau-Ting
机构信息
Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.
Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C.
出版信息
In Vivo. 2018 Jul-Aug;32(4):955-960. doi: 10.21873/invivo.11334.
BACKGROUND/AIM: Our previous cDNA microarray study revealed increased cellular mRNA levels of a panel of genes, including kallikrein-8 (KLK8), after long-term telbivudine treatment in chronic hepatitis B patients. The aim of this study was to verify whether serum protein levels of KLK8, a cancer-related enzyme, are indeed increased after telbivudine treatment.
PATIENTS AND METHODS
A total of 83 chronic hepatitis B patients receiving telbivudine for >2 years were retrospectively analyzed. Serum KLK8 protein and estimated glomerular filtration rate (eGFR) changes were compared before and after treatment.
RESULTS
Both serum KLK8 protein and eGFR increased significantly after long-term telbivudine treatment (paired t-test: KLK8, p<0.001; eGFR, p=0.001). No direct correlation was found between KLK8 increase and eGFR change. However, eGFR change was positively associated with post-treatment KLK8 levels following adjustment for body height (p<0.001).
CONCLUSION
Telbivudine treatment resulted in increased levels of serum KLK8 protein. Furthermore, eGFR increase was associated with body height-adjusted, post-treatment KLK8 levels.
背景/目的：我们之前的cDNA微阵列研究显示，在慢性乙型肝炎患者长期接受替比夫定治疗后，一组基因（包括激肽释放酶8，KLK8）的细胞mRNA水平升高。本研究旨在验证癌症相关酶KLK8的血清蛋白水平在替比夫定治疗后是否确实升高。
患者与方法
对83例接受替比夫定治疗超过2年的慢性乙型肝炎患者进行回顾性分析。比较治疗前后血清KLK8蛋白和估计肾小球滤过率（eGFR）的变化。
结果
长期替比夫定治疗后，血清KLK8蛋白和eGFR均显著升高（配对t检验：KLK8，p<0.001；eGFR，p=0.001）。未发现KLK8升高与eGFR变化之间存在直接相关性。然而，在调整身高后，eGFR变化与治疗后KLK8水平呈正相关（p<0.001）。
结论
替比夫定治疗导致血清KLK8蛋白水平升高。此外，eGFR升高与调整身高后的治疗后KLK8水平相关。
Zotero 插件